BTIG Research Lowers Evolent Health (NYSE:EVH) Price Target to $29.00

Evolent Health (NYSE:EVH) had its price objective reduced by stock analysts at BTIG Research from $36.00 to $29.00 in a research report issued on Tuesday, MarketBeat reports. The brokerage presently has a “buy” rating on the technology company’s stock. BTIG Research’s price target points to a potential upside of 151.74% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. KeyCorp initiated coverage on Evolent Health in a research report on Friday, October 11th. They issued an “overweight” rating and a $35.00 price target on the stock. Truist Financial restated a “buy” rating and issued a $33.00 price target on shares of Evolent Health in a research report on Tuesday, August 27th. Barclays dropped their price target on Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Stephens cut Evolent Health from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $38.00 to $16.00 in a research report on Friday, November 8th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $20.00 price target on shares of Evolent Health in a research report on Tuesday, November 12th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Evolent Health has an average rating of “Buy” and an average target price of $26.18.

Evolent Health Stock Down 1.6 %

EVH opened at $11.52 on Tuesday. The business’s 50-day simple moving average is $20.77 and its 200-day simple moving average is $23.18. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. Evolent Health has a one year low of $11.17 and a one year high of $35.00. The stock has a market capitalization of $1.34 billion, a P/E ratio of -12.87 and a beta of 1.45.

Hedge Funds Weigh In On Evolent Health

A number of large investors have recently bought and sold shares of EVH. Valeo Financial Advisors LLC bought a new position in Evolent Health in the second quarter worth about $2,705,000. Salem Investment Counselors Inc. lifted its holdings in Evolent Health by 88.1% in the second quarter. Salem Investment Counselors Inc. now owns 225,901 shares of the technology company’s stock worth $4,319,000 after acquiring an additional 105,780 shares during the last quarter. Values First Advisors Inc. lifted its holdings in Evolent Health by 53.0% in the second quarter. Values First Advisors Inc. now owns 26,546 shares of the technology company’s stock worth $508,000 after acquiring an additional 9,193 shares during the last quarter. SeaCrest Wealth Management LLC lifted its holdings in Evolent Health by 6.3% in the second quarter. SeaCrest Wealth Management LLC now owns 10,200 shares of the technology company’s stock worth $195,000 after acquiring an additional 600 shares during the last quarter. Finally, HMS Capital Management LLC lifted its holdings in Evolent Health by 42.5% in the second quarter. HMS Capital Management LLC now owns 10,569 shares of the technology company’s stock worth $202,000 after acquiring an additional 3,150 shares during the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.